Cancer Cell Surface Sugar Shields Block Anticancer Peptide Killing
Heparan sulfate on tumor cell surfaces inhibited lytic anticancer peptide activity, identifying a tumor resistance mechanism and suggesting heparanase combination therapy to unmask cancer cells for peptide killing.
Quick Facts
What This Study Found
Heparan sulfate on tumor cell surfaces inhibited lytic anticancer peptide activity, identifying a tumor resistance mechanism and suggesting heparanase combination therapy to unmask cancer cells for peptide killing.
Key Numbers
How They Did This
research study.
Why This Research Matters
Relevant for peptide research.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
Trust & Context
- Key Stat:
- Key finding Heparan sulfate on tumor cell surfaces inhibited lytic anticancer peptide activity, identifying a tumor resistance mechanism and suggesting heparanase
- Evidence Grade:
- emerging evidence.
- Study Age:
- Published in 2009.
- Original Title:
- The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.
- Published In:
- BMC cancer, 9, 183 (2009)
- Authors:
- Fadnes, Bodil(2), Rekdal, Oystein(3), Uhlin-Hansen, Lars(2)
- Database ID:
- RPEP-01477
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Cancer Cell Surface Sugar Shields Block Anticancer Peptide Killing
What was found?
Heparan sulfate on tumor cell surfaces inhibited lytic anticancer peptide activity, identifying a tumor resistance mechanism and suggesting heparanase combination therapy to unmask cancer cells for peptide killing.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01477APA
Fadnes, Bodil; Rekdal, Oystein; Uhlin-Hansen, Lars. (2009). The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.. BMC cancer, 9, 183. https://doi.org/10.1186/1471-2407-9-183
MLA
Fadnes, Bodil, et al. "The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.." BMC cancer, 2009. https://doi.org/10.1186/1471-2407-9-183
RethinkPeptides
RethinkPeptides Research Database. "The anticancer activity of lytic peptides is inhibited by he..." RPEP-01477. Retrieved from https://rethinkpeptides.com/research/fadnes-2009-the-anticancer-activity-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.